

## PRESS RELEASE

### Financial Results of EVROFARMA Group of Companies 2025

**EVROFARMA S.A.** Group of Companies announces its consolidated financial results in accordance with International Financial Reporting Standards (IFRS) for the financial year ended 31 December 2025.

At Group level profit after tax amounted to €3,526 thousand, compared to €2,280 thousand in the previous financial year, reflecting an increase of 55%. At company level, profit after tax reached €1,815 thousand, compared to €1,409 thousand in the corresponding period of the prior year, recording an increase of 29%.

At Group level profit before tax amounted to €4,526 thousand, increased by 57% compared to €2,888 thousand in the previous financial year. Correspondingly, profit before tax at company level amounted to €2,038 thousand, increased by 24% compared to €1,647 thousand in the comparative period.

At Group level earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to €6,711 thousand (adjusted excluding provisions: €6,841 thousand), increased by 24% compared to €5,426 thousand in the previous financial year. At company level, EBITDA amounted to €2,905 thousand, compared to €2,879 thousand in the previous period, representing an increase of 1%.

Group's gross profit reached €12,050 thousand, increased by 18% compared to €10,226 thousand in the previous financial year, while at company level gross profit amounted to €8,141 thousand, increased by 6% compared to €7,652 thousand in the comparative period.

The Group's consolidated turnover amounted to €49,443 thousand, increased by 8.1% compared to €45,719 thousand in the previous financial year, while company's turnover amounted to €47,152 thousand, recording an increase of 6.9% compared to €44,129 thousand in the previous year. Company's exports amounted to €12,937 thousand, compared to €10,272 thousand, recording an increase of 26%, representing 27% of total sales.

During the first quarter of 2026, an investment project of €7.2 million was completed, mainly related to the expansion of the strained yogurt production line. Net debt decreased to €10.4 million from €13.4 million in the previous period, representing a reduction of €3.0 million, reflecting the positive development of the Group's financial performance.

The financial year 2026 commenced in an environment of geopolitical tensions and ongoing challenges in the markets. The Group continues to pursue its business priorities in a disciplined manner, with emphasis on enhancing operational efficiency and improving cash flows. Management closely monitors international and domestic developments and the overall economic environment, adapting its operations with a focus on meeting the needs of consumers and customers, as well as safeguarding shareholders' interests, aiming at long-term growth. The continuing increase in transportation costs, as well as the pressure on consumers' purchasing power, remain factors of concern and are taken into account by management.

The Board of Directors, taking into consideration the financial results of 2025, decided to propose to the General Meeting of Shareholders the approval of a gross dividend distribution of €0.06 per share.

The Financial Report for the period 01.01.2025-31.12.2025 was published on 17/04/2026, after the close of the Athens Stock Exchange session and is available online on:

- Company's website <http://www.evrofarma.gr>
- ATHEX Group website <http://www.athexgroup.gr>.